Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ultragenyx Pharmaceutical (RARE) Gross Profit (2018 - 2025)

Ultragenyx Pharmaceutical has reported Gross Profit over the past 8 years, most recently at $177.9 million for Q4 2025.

  • Quarterly Gross Profit rose 20.65% to $177.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $564.0 million through Dec 2025, up 16.77% year-over-year, with the annual reading at $564.0 million for FY2025, 16.77% up from the prior year.
  • Gross Profit was $177.9 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $131.9 million in the prior quarter.
  • Over five years, Gross Profit peaked at $177.9 million in Q4 2025 and troughed at $73.8 million in Q1 2022.
  • The 5-year median for Gross Profit is $96.1 million (2021), against an average of $105.3 million.
  • Year-over-year, Gross Profit surged 187.16% in 2021 and then dropped 21.62% in 2022.
  • A 5-year view of Gross Profit shows it stood at $79.9 million in 2021, then grew by 22.72% to $98.0 million in 2022, then increased by 17.62% to $115.3 million in 2023, then increased by 27.91% to $147.5 million in 2024, then grew by 20.65% to $177.9 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Gross Profit are $177.9 million (Q4 2025), $131.9 million (Q3 2025), and $143.5 million (Q2 2025).